- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
138.79
+2.22(+1.63%)
After Hours
138.79
0.00(0.00%)
- Real-time Data
- Volume:726,308
- Bid/Ask:135.68/139.68
- Day's Range:131.88 - 138.97
NTLA Overview
- Prev. Close
- 136.57
- Day's Range
- 131.88-138.97
- Revenue
- 51.52M
- Open
- 136.26
- 52 wk Range
- 16.54-202.45
- EPS
- -2.46
- Volume
- 726,308
- Market Cap
- 10.08B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 2,238,502
- P/E Ratio
- -
- Beta
- 2.14
- 1-Year Change
- 620.99%
- Shares Outstanding
- 72,648,954
- Next Earnings Date
- Aug 05, 2021
What is your sentiment on Intellia Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.
Intellia Therapeutics Inc News
- H.C. Wainwright Stick to Their Buy Rating for Intellia Therapeutics
- ByInvesting.com-
H.C. Wainwright analyst Michael King maintained a Buy rating on Intellia Therapeutics (NASDAQ:NTLA) on Monday, setting a price target of $171, which is approximately 11.76% above...
- Why I’m smiling today…
- ByETF Trends-
I’m writing you today with a big smile on my face. Because humanity just achieved a MONUMENTAL scientific breakthrough. This breakthrough will save sick children and unite broken...
Intellia Therapeutics Inc Analysis
- A Comprehensive Guide to Genomic ETFs
Scientists across the world are researching some inconceivable biological concepts like creating a gene-edited human baby or a human-animal hybrid embryo or curing diabetes and...
- Major Indices Surge Double Digits in First Half of 2021
The market may be pretty slow right now, but totals for the first half and second quarter show that stocks have actually been on a tear for most of 2021. Furthermore, those...
- As Earnings Season Kicks Off, 2 ETFs Worth Watching For Buyable Dips
Recent days brought new all-time-highs to the S&P 500 and NASDAQ 100, which are up about 14% and 12%, respectively, in 2021. Meanwhile, the Dow Jones Industrial Average, which...
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Buy |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 351.24 | 353.77 | 347.70 | -0.71 | -0.20% | 12.41M | NASDAQ | |||
| 2,712.60 | 2,714.60 | 2,666.40 | +15.5 | +0.58% | 1.04M | NASDAQ | |||
| 198.15 | 202.22 | 192.20 | +0.65 | +0.33% | 30.18M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 45.68 | 45.86 | 44.07 | +1.72 | +3.91% | 45.64M | NYSE | |||
| 197.38 | 197.44 | 192.00 | -2.71 | -1.35% | 20.12M | NYSE | |||
| 54.06 | 54.16 | 53.26 | +0.38 | +0.71% | 16.38M | NASDAQ | |||
| 21.72 | 21.77 | 21.53 | +0.15 | +0.70% | 10.74M | NYSE | |||
| 13.64 | 13.68 | 13.42 | +0.10 | +0.74% | 2.37M | NYSE | |||
| 6.52 | 6.556 | 6.45 | +0.020 | +0.31% | 6.80M | NYSE | |||
| 64.03 | 64.65 | 63.95 | -0.06 | -0.09% | 612.48K | NYSE | |||
| 1.08 | 1.10 | 1.06 | -0.0100 | -0.92% | 3.09M | NYSE | |||
| 2.41 | 3.27 | 2.38 | +0.150 | +6.64% | 114.90M | NASDAQ | |||
| 0.61 | 0.00 | 0.00 | +0.0058 | +0.96% | 676.00K | NYSE | |||
| 19.74 | 19.84 | 18.99 | +0.48 | +2.49% | 7.61M | NYSE |
Intellia Therapeutics Inc Company Profile
Intellia Therapeutics Inc Company Profile
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
Read More
- 2021-07-21 09:13:22
time to buy a few and hold me thinks - 2021-07-06 15:38:51Any thought about this stock?
- 2021-07-01 15:20:12waiting to get back in
- 2021-06-30 15:39:11Feels too aggressive
- 2021-06-28 21:30:15
GLOP and CEPU, this are the next homeruns - 2021-06-28 18:41:32
Buy???? - 2021-06-28 18:19:41
I'm really surprise about how empty this forum is on a day like this!Show previous replies (1)- 2021-06-28 18:23:32
crazy move though....would like to see more on Crisper on follow through - 2021-06-28 18:27:05What do you mean? It's just you and i.. nobody else is posting a reaction here.
- 2021-06-28 20:21:49I'm just bugging you! in a friendly way! Your right but if the crystal ball was working you wouldn't have been surprised is what I mean
- 2021-06-26 18:17:27https://www.fiercebiotech.com/biotech/first-human-trial-results-intellia-shows-world-gene-editing-has-arrived
- 2021-06-26 18:18:07Great news for investors in Intellia and other similar companies using Crispr cas9
- 2021-06-16 19:05:14what's happening here
- 2021-01-28 19:45:42
Be patient guys, just hold and fly to the moon!🚀🚀 - 2021-01-22 07:44:52Read Jennifer Doudna's book guys before you make an investment into this company.
- 2021-01-27 14:39:07I cant tell if this a positive or negative comment?
- 2021-02-03 15:12:18pls a bit more straightforward. whats the insight you got?
- 2021-02-05 02:05:42
9
- 2020-12-28 21:20:52What was that from +11 percent -2 percent?what happened?
- 2020-05-19 18:19:38Boom! Out.
- 2020-03-26 21:35:33Looks like this is ready to pop any day now.
- 2020-01-18 20:26:50NTLA is gonna run up into the 17 to 18 dollar range by the end of january. This is not trading advice
- 2020-01-31 14:07:59nice prediction :) Jan 31 - trading at 12.57 :)
- 2020-02-11 17:39:30he was a month and half off end of Feb into March
- 2019-10-08 14:09:45
Inept workers + inept managers = worthless bottom! I was right.- 2021-06-30 15:13:01emmmmm.... lol
- 2019-09-04 21:55:56Touch the bottom? 12, 11 or 10? Target 9?
- 2018-02-06 20:00:18wish it can go up to 40 + after Feb
- 2020-01-18 20:24:31Profit source has NTLA at $18 by end of january. So we can hope. This is not trading advice or stratedgy
- 2016-11-28 21:36:57$NTLA has both analyst saying “BUY” with an ave 12 month target price of $35.50 which is 109% at its closing price of $16.96
- 2016-11-28 21:49:54That is 109% ROI
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.